Tymlos infusion for subcutaneous organization contains abaloparatide, a manufactured 34 amino corrosive peptide.
Abaloparatide is a simple of human parathyroid hormone related peptide, PTHrP(1-34).
It has 41% homology to hPTH(1-34) (human parathyroid hormone 1-34) and 76% homology to hPTHrP(1-34) (human parathyroid hormone-related peptide 1-34).
Generic Name: abaloparatide injection
Tymlos is demonstrated for the treatment of postmenopausal ladies with osteoporosis at high hazard for crack characterized as a background marked by osteoporotic break, different hazard factors for crack, or patients who have fizzled or are bigoted to other accessible osteoporosis treatment.
In postmenopausal ladies with osteoporosis, TYMLOS decreases the danger of vertebral cracks and nonvertebral breaks.
The suggested dose of TYMLOS is 80 mcg subcutaneously once every day.
Aggregate utilization of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for over 2 years amid a patient's lifetime isn't suggested.
Patients ought to get supplemental calcium and nutrient D if dietary admission is deficient.
Tymlos Side Effects:
The accompanying unfriendly responses are portrayed in more prominent detail in different areas:
Hypercalciuria and Urolithiasis